AKT1 and systemic sclerosis: To explore the pathways involved in the effects of EVs isolated from SSc patients on HUVECs and smooth muscle cells, which is an aspect not yet investigated, we conducted experiments by using inhibitors targeting Akt/PI3K, AMPK, MEK1/2/ERK1/2, PKA, and CAMKII.